Suven Life Sciences (BOM:530239) Cyclically Adjusted Revenue per Share: ₹16.37 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530239 Suven Life Sciences Ltd BOM:530239
40 GF Score
Price ₹350.15
GF Value ₹123.90
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Suven Life Sciences Cyclically Adjusted Revenue per Share?

Suven Life Sciences BOM:530239 +4.04% 40 Cyclically Adjusted Revenue per Share is ₹16.37 as of Jun. 2026. GuruFocus rates BOM:530239 with a GF Score™ of 40/100 and a GF Value™ of ₹123.90 (Significantly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Suven Life Sciences's adjusted revenue per share for the three months ended in Jun. 2026 was ₹0.126. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹16.37 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Suven Life Sciences's average Cyclically Adjusted Revenue Growth Rate was -33.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -19.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Suven Life Sciences was -10.70% per year. The lowest was -19.60% per year. And the median was -15.15% per year.

As of today (2026-09-18), Suven Life Sciences's current stock price is ₹350.15. Suven Life Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹16.37. Suven Life Sciences's Cyclically Adjusted PS Ratio of today is 21.39.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Suven Life Sciences was 28.44. The lowest was 1.64. And the median was 3.92.


Suven Life Sciences  (BOM:530239) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Suven Life Sciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=350.15/16.368
=21.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Suven Life Sciences was 28.44. The lowest was 1.64. And the median was 3.92.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Suven Life Sciences Cyclically Adjusted Revenue per Share Related Terms


Suven Life Sciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Suven Life Sciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suven Life Sciences Cyclically Adjusted Revenue per Share Chart

Suven Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.41 31.94 26.59 20.94 16.07

Suven Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.23 21.57 21.70 16.07 16.37

BOM:530239 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Life Sciences Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Suven Life Sciences's Cyclically Adjusted PS Ratio falls into.


BOM:530239
40GF Score
Suven Life Sciences Ltd BOM:530239
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suven Life Sciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Suven Life Sciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.126/167.3573*167.3573
=0.126

Current CPI (Jun. 2026) = 167.3573.

Suven Life Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 11.029 96.780 19.072
201412 10.057 96.780 17.391
201503 8.012 97.163 13.800
201506 7.311 99.841 12.255
201509 8.453 101.753 13.903
201512 8.145 102.901 13.247
201603 12.255 102.518 20.006
201703 0.000 105.196 0.000
201806 13.876 111.317 20.862
201809 6.481 115.142 9.420
201812 0.152 115.142 0.221
201906 0.115 120.880 0.159
201909 0.100 123.175 0.136
201912 0.201 126.235 0.266
202003 0.627 124.705 0.841
202006 0.103 127.000 0.136
202009 0.650 130.118 0.836
202012 0.110 130.889 0.141
202103 0.113 131.771 0.144
202106 0.145 134.084 0.181
202109 0.086 135.847 0.106
202112 0.321 138.161 0.389
202203 0.305 138.822 0.368
202206 0.224 142.347 0.263
202209 0.278 144.661 0.322
202212 0.170 145.763 0.195
202303 0.120 146.865 0.137
202306 0.174 150.280 0.194
202309 0.140 151.492 0.155
202312 0.112 152.924 0.123
202403 0.109 153.035 0.119
202406 0.046 155.789 0.049
202409 0.118 157.882 0.125
202412 0.074 158.323 0.078
202503 0.067 157.552 0.071
202506 0.086 159.755 0.090
202509 0.041 162.289 0.042
202512 0.123 163.281 0.126
202603 0.058 164.272 0.059
202606 0.126 167.357 0.126

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹16.37 mean?
Suven Life Sciences (BOM:530239) has a Cyclically Adjusted Revenue per Share of ₹16.37 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Suven Life Sciences and its competitors.
Is Suven Life Sciences' Cyclically Adjusted Revenue per Share too high?
Suven Life Sciences' current Cyclically Adjusted Revenue per Share is ₹16.37. Overall, Suven Life Sciences has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Suven Life Sciences' Cyclically Adjusted Revenue per Share compare to ZTS?
Suven Life Sciences' Cyclically Adjusted Revenue per Share of ₹16.37 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Suven Life Sciences and its competitors. Suven Life Sciences's current Cyclically Adjusted Revenue per Share is ₹16.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suven Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Suven Life Sciences (BOM:530239) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹123.90, compared to a current price of ₹350.15 — trading 182.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹16.37. Suven Life Sciences' overall GF Score™ is 40/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Suven Life Sciences (BOM:530239), the current Cyclically Adjusted Revenue per Share is ₹16.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suven Life Sciences (BOM:530239) Overvalued in 2026?

Based on GuruFocus' analysis, Suven Life Sciences stock appears to be overvalued. The current stock price of ₹350.15 is trading 182.6% above its estimated GF Value™ of ₹123.90. GuruFocus considers Suven Life Sciences to be Significantly Overvalued.

Key valuation signals for BOM:530239:

  • Cyclically Adjusted Revenue per Share: ₹16.37
  • GF Value™: ₹123.90 vs. price of ₹350.15 (182.6% above fair value)
  • GF Score™: 40/100 with 9 warning signs

No single metric tells the full story. See the BOM:530239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Suven Life Sciences Business Description

Other Exchanges SUVEN:India
Address Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
40GF Score

Get the complete analysis for BOM:530239

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹350.15
Price
₹123.90
GF Value